A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab

Study Summary

The aim of this study is to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.

Conditions

Multiple Sclerosis

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment261 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.151433+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.